Download Poster (695 KB)
Poster presented at American Association of the Study of Liver Diseases (AASLD) meeting in San Francisco California.
Develop a urine test using a panel of select genetic and epigenetic markers for the early detection of primary and recurrent HCC.
Hepatocellular carcinoma (HCC) or liver cancer is an aggressive disease and one of the fastest growing cancers by incidence in the United States. Early detection is the key for effective treatment of HCC as the 5-year survival rate is 26% in early stage HCC as compared to only 2% when found after spreading to distant organs. The current marker, alpha-feto protein (AFP) and its fucosylated glycoform, L3, are of limited value with only 40-60% sensitivity.
Gastroenterology | Hepatology
Hann, Hie-Won; Jain, Surbhi; Chang, Ting-Tsung; Hu, Chi-Tan; Lin, Selena; Song, Wei; and Su, Ying-Hsiu, "Detection of genetic and epigenetic DNA markers in urine for the early detection of primary and recurrent hepatocellular carcinoma" (2015). Division of Gastroenterology and Hepatology Posters.